10.12.2012 Views

Abstracts (complete list) - Wissenschaft Online

Abstracts (complete list) - Wissenschaft Online

Abstracts (complete list) - Wissenschaft Online

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

Monika Lindemann, Alexandra Schumann, Melanie Fiedler, Camino Valentin-Gamazo,<br />

Dietmar Knop, Christoph E. Broelsch, Michael Roggendorf, Hans Grosse-Wilde<br />

Transfer of adoptive immunity to hepatitis B virus by liver<br />

transplantation*<br />

Liver transplantation is often the ultimate option of therapy for chronically hepatitis B<br />

virus (HBV) infected patients. Despite antiviral therapy reinfection is still a problem.<br />

Adoptive transfer of HBV immunity with the liver after vaccination of living liver donors<br />

could be a new approach to prevent reinfection in the recipients. The period in which to<br />

achieve HBV immunity in donors is usually short (1-2 months). In this study we<br />

vaccinated living liver donors in a short time immunization protocol (4 injections in two<br />

weeks intervals) using Hepimmune (Berna Biotech), a recombinant vaccine that<br />

contains the PreS1, PreS2, and S proteins of HBV. Humoral (anti-HBs titer) and cellular<br />

(proliferation assay) immune responses were examined prior to each immunization, pre<br />

and post transplantation. So far 14 patients received a liver from an immunized living<br />

donor. In 4 recipients adoptive immune transfer was observed. One HBV naive recipient<br />

developed humoral and cellular immune responses post transplantation (anti-HBs of<br />

1800 IU/l and stimulation index of 4.9). Two further naive recipients showed cellular<br />

immune responses (stimulation indices of 2.7 and 7.1) and in one chronically HBV<br />

infected recipient specific immune responses were measurable at day 5 (anti-HBs of 120<br />

IU/l) and vigorously increased thereafter (anti-HBs of 58000 IU/l and stimulation index<br />

of 3.1). This finding most likely reflects the boosting of HBV specific immunity by HBs<br />

antigen persisting in the host. Taken together, we were able to show that HBV specific<br />

humoral and cellular immunity can be transferred to recipients with the liver graft.<br />

Thereby, the reinfection in chronically HBV infected recipients could be prevented.<br />

*This study was partially supported by the DFG (KFO 117).

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!